AKT1 and urinary bladder carcinoma: IGF2 regulates PI3K/AKT/mTOR signaling pathway, targeting on IGF2 is a new therapeutic strategy for bladder cancer, and obstructing IGF2 signaling way could make cancer cell reacquire sensitivity to Taxol.